Press release

Data Suggests New Guidelines in Stroke Care Have Led to Record Numbers of Patients Treated

Sponsored by Businesswire

May is Stroke Awareness Month and in commemoration, iSchemaView, the
worldwide leader in advanced imaging for stroke, is releasing its first
market intelligence data from RAPID. The RAPID platform is designed to
provide physicians with fast, fully automated, and easy-to-interpret
imaging that facilitates clinical decision-making around stroke. Stroke
afflicts around 800,000 Americans each year and ranks as the number five
cause of death and number one cause of disability in the United States.
New RAPID data reveals that over 40,000 more patients’ lives were
impacted in 2018 over 2017 via this advanced technology, more than
doubling the number of patients scanned and thrombectomies indicated by

This press release features multimedia. View the full release here:

Acute Stroke Patients Scanned at Sites Using Rapid (Graphic: Business Wire)

Acute Stroke Patients Scanned at Sites Using Rapid (Graphic: Business Wire)

iSchemaView’s RAPID has changed how physicians approach stroke care.
From 2017 to 2018 there was over a 100% increase in patients imaged with
RAPID worldwide (41,125 in 2017 and 82,365 in 2018). Perfusion imaging
criteria was met for thrombectomy in 12,285 patients in 2017 and 25,269
in 2018. Based on the first quarter of 2019, RAPID is on pace to image
over 132,500 patients in 2019 and identify over 40,000 potential
patients for thrombectomies. The platform is also estimated to process
over 250,000 total scans this year.

While the above represents dramatic overall growth in patients addressed
and thrombectomies indicated around the world, there was also
significant same-site growth. Looking only at care sites active with the
RAPID platform in 2017 as compared to the same sites in 2018, there was
over a 50% growth in patients addressed (39,955 in 2017 and 60,821 in
2018), and potential thrombectomies indicated (11,811 in 2017 and 17,742
in 2018).

This dramatic expansion in patients scanned tracks with new 2018
American Heart Association and American Stroke Association guidelines
that have dramatically altered the management of acute stroke. These new
guidelines were established after a series of studies were conducted and
published by iSchemaView co-founder, Dr. Greg Albers and others.

“RAPID has greatly impacted our ability to offer life- and
disability-saving care to our patients,” said Cherylee Chang, M.D.,
medical director, Neuroscience Institute/Neurocritical Care at The
Queen’s Medical Center. “In 2017 we performed 37 thrombectomies; this
increased to 93 in 2018 and we have already exceeded 30 cases in the
first 3 months of 2019. Due to the ability of our stroke team, which
includes our neurointerventionalists, to receive immediate results of
RAPID’s perfusion imaging, our median door-to-puncture time is 46
minutes. RAPID has revolutionized stroke care.”

“It is now just over a year since the simultaneous publication of DEFUSE
3 and the new 24-hour stroke treatment guidelines. Taking a look at the
latest treatment numbers, it seems clear that the imaging-based studies
have already made a huge impact on stroke care worldwide,” said Dr. Greg
Albers, professor of neurology at Stanford University, director of the
Stanford Stroke Center and co-founder of iSchemaView. “By building on
the artificial intelligence and advanced imaging technology in RAPID, we
will continue to contribute to increased treatment rates which will lead
to a major reduction in stroke disability and mortality.”

About iSchemaView

iSchemaView is the worldwide leader in advanced imaging for stroke.
Installed in over 1,200 hospitals, iSchemaView’s RAPID (automated CTP,
MRI, CTA and ASPECTS), with enhanced AI framework, is the most advanced
stroke imaging platform. In clinical trials, RAPID has been shown to aid
in the selection of patients in early and late-window stroke trials,
including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition
to achieving the best clinical outcomes and largest treatment effects
ever obtained, these landmark studies led to new American Heart
Association and American Stroke Association guidelines and have
dramatically altered the management of acute stroke around the
world. For more information, visit